76464-50-1 Usage
Description
1-Chloro-4-nitro-2-propoxybenzene is a chemical compound with the molecular formula C9H10ClNO4. It is a yellow to brown solid that serves as an important intermediate in the synthesis of various products.
Uses
Used in Pharmaceutical Industry:
1-Chloro-4-nitro-2-propoxybenzene is used as a key intermediate for the synthesis of pharmaceuticals, contributing to the development of new drugs and medicines.
Used in Agrochemical Industry:
1-Chloro-4-nitro-2-propoxybenzene is also utilized as an intermediate in the production of agrochemicals, playing a role in the creation of pesticides and other agricultural products to protect crops.
Used in Dye Production:
1-Chloro-4-nitro-2-propoxybenzene is used as a raw material in the manufacturing of dyes, contributing to the coloration of various materials.
Used in Perfume Production:
It serves as a starting material for the synthesis of perfumes, adding to the fragrance industry by providing aromatic compounds.
However, due to its toxic nature, it is crucial to handle 1-Chloro-4-nitro-2-propoxybenzene with care to avoid skin and eye irritation, as well as potential respiratory and central nervous system damage. Safety protocols must be strictly followed during its use and manipulation.
Check Digit Verification of cas no
The CAS Registry Mumber 76464-50-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,6,4,6 and 4 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 76464-50:
(7*7)+(6*6)+(5*4)+(4*6)+(3*4)+(2*5)+(1*0)=151
151 % 10 = 1
So 76464-50-1 is a valid CAS Registry Number.
76464-50-1Relevant articles and documents
ORGANIC COMPOUNDS
-
Page/Page column 48, (2008/06/13)
The present invention relates to quinazolinone compounds of the formula wherein R2, R3, R5, R6 R7 and R8 are as defined in the specification and in the claims, in free form or in salt form , processes for their preparation and their use as pharmaceuticals, particularly in the treatment of disorders ameliorated by administration of TRPV1 antagonists.
